AmbioPharm, Inc.

AmbioPharm, Inc. is a specialized provider of peptide manufacturing and development services, focusing on high-quality Active Pharmaceutical Ingredients (APIs) for various applications across the pharmaceutical, biotech, and cosmetic sectors. Founded in 2006 and headquartered in North Augusta, US, AmbioPharm, Inc. specializes in peptide manufacturing.

The company has undertaken three deals, with its latest funding round being a Buyout, raising USD 23. 99 mn from MVM Partners. The CEO is Chris Bai, with Tim Nieters also holding a leadership role. AmbioPharm specializes in peptide manufacturing and development services, offering a comprehensive range of products including Active Pharmaceutical Ingredients (APIs) for peptide vaccines and various cosmetic peptide formulations.

The company employs advanced synthesis techniques, including solid-phase, liquid-phase, and hybrid methods, to produce high-quality peptides catering to clients in the pharmaceutical, biotech, and cosmetic industries. Their products are utilized in a wide array of applications from preclinical research to commercial drug development, facilitating the creation of novel therapeutic solutions for rare diseases. AmbioPharm also provides analytical development and validation services to ensure compliance with stringent quality standards, serving a diverse global market, including major pharmaceutical firms, clinical research laboratories, and cosmetic formulators. AmbioPharm operates on a B2B model, generating revenue primarily through partnerships and contracts with pharmaceutical and biotech companies, clinical research labs, and academic institutions.

Transactions typically involve the provision of custom peptide synthesis services and the manufacturing of GMP and non-GMP peptides, with clients engaging AmbioPharm for both large-scale and small-batch projects. The revenue structure is based on fixed pricing agreements for custom services, offering tailored peptide products that adhere to specific requirements. The company's flagship products include biologically active peptides for therapeutic applications and cosmetic formulations, with pricing models reflecting the complexity and scale of peptide synthesis. AmbioPharm's commitment to rapid delivery and stringent quality controls positions it competitively in the peptide manufacturing market.

AmbioPharm plans to expand its product offerings, focusing on the development of new peptide formulations in therapeutic and cosmetic applications. The company targets to enter additional global markets, particularly in Europe and Asia, by 2025. Recent funding from Lake Bleu Capital will support these initiatives, enhancing research capabilities and production capacity to meet increasing market demands.